Cultured endothelial progenitor cells treated with thymosin beta4
How the study was set up
Cultured endothelial progenitor cells were exposed to thymosin beta4 with inhibitors of several signaling pathways.
What the researchers measured
Directional cell migration and phosphorylation of Akt, eNOS, and ERK were measured.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
Blocking PI3K or eNOS reduced migration, while ERK inhibition did not substantially do so. The distinction supports a pathway hypothesis in cells rather than a clinical vessel-repair outcome.
What this does not establish
A cell-migration assay with thymosin beta4 does not establish vascular repair in people or equivalence to TB-500.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.